GHRH antagonists for use in a method of treating sarcoidosis
Inventors
Mirsaeidi, Mehdi • Zhang, Chongxu • Schally, Andrew V. • Cai, Renzhi
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
United States Government Represented By Department Veterans Affairs AS • United States Department of Veterans Affairs
MemberUniversity of MiamiUniversity of MiamiThe University of Miami, established in 1925 and based in Coral Gables, Florida, is a private research university recognized for its comprehensive academic offerings, robust research infrastructure, and strong interdisciplinary focus. Home to more than 19,000 students and with more than 400 acres of campuses across the Miami region, its mission encompasses education, research, innovation, and community service. The institution supports clinical, biomedical, marine, and atmospheric research initiatives, delivers diverse undergraduate and graduate programs, and maintains numerous research centers and institutes dedicated to scientific, medical, and societal advancements.
The University of Miami, established in 1925 and based in Coral Gables, Florida, is a private research university recognized for its comprehensive academic offerings, robust research infrastructure, and strong interdisciplinary focus. Home to more than 19,000 students and with more than 400 acres of campuses across the Miami region, its mission encompasses education, research, innovation, and community service. The institution supports clinical, biomedical, marine, and atmospheric research initiatives, delivers diverse undergraduate and graduate programs, and maintains numerous research centers and institutes dedicated to scientific, medical, and societal advancements.
Publication Number
US-12377135-B2
Publication Date
2025-08-05
Expiration Date
Abstract
The disclosure provides a method of treating sarcoidosis, the method comprising administering a GHRH antagonist to mammalian subject in need thereof.
Core Innovation
The invention provides a method of treating sarcoidosis by administering a GHRH antagonist to a mammalian subject in need thereof. The disclosed approach targets growth hormone-releasing hormone activity through use of a GHRH receptor antagonist in the therapeutic context of sarcoidosis. The document focuses on sarcoidosis treatment, including pulmonary sarcoidosis.
The disclosed GHRH antagonists are defined as peptide antagonists according to Formula I and as set forth by SEQ ID NO:2, with permitted substituent residues. Exemplary antagonists include MIA-602, MIA-604, MIA-606, MIA-610, MIA-640, and MIA-690. The document also identifies related sequence information including SEQ ID NO:1 (hGHRH(1-29)NH2).
The method includes administering the GHRH antagonist via one or more delivery routes, including intranasal, inhalation, intrapulmonary, intra-airway, intrabronchial, intratracheal, and other listed routes. The document further describes therapeutic effect criteria and supports the approach with in vivo and ex vivo evidence using sarcoid-like granuloma models, including reduced lung inflammation and changes in inflammation-associated markers.
Claims Coverage
The independent claim is directed to a sarcoidosis treatment method by administering a GHRH antagonist to a mammalian subject in need thereof. The dependent claims define the GHRH antagonist candidates and compositions using Formula I/SEQ ID NO:2, optionally narrow the indication to pulmonary sarcoidosis, and constrain delivery by specifying multiple administration routes.
Treating sarcoidosis by administering a GHRH antagonist
A method of treating sarcoidosis by administering a GHRH antagonist to a mammalian subject in need thereof.
GHRH antagonist defined by Formula I/SEQ ID NO:2
Using a GHRH antagonist that includes the amino-acid sequence of Formula I/SEQ ID NO:2 with defined variable residue options including R1, A4, A6, A8, A10, A11, A12, A15, A17, A20, A21, A29, and R2 and R3.
Pulmonary sarcoidosis treatment
The method is specified as being for pulmonary sarcoidosis.
Administration using specified delivery routes
Administering the GHRH antagonist using one of multiple specified routes including intradermal, intramuscular, intraperitoneal, intravenous, intraarterial, subcutaneous, epidural, sublingual, intranasal, intracerebral, intraventricular, intrathecal, intravaginal, transdermal, rectally, inhalation, intrapulmonary, intra-airway, intrabronchial, intratracheal, and topical delivery.
Intranasal/inhalation/intrapulmonary/intra-airway/intrabronchial/intratracheal delivery
Administering a GHRH antagonist using intranasal, inhalation, intrapulmonary, intra-airway, intrabronchial, or intratracheal delivery.
Overall, claim coverage centers on treating sarcoidosis with a GHRH antagonist, where the antagonists are defined by Formula I/SEQ ID NO:2 (with variable residue options), the indication may be narrowed to pulmonary sarcoidosis, and administration can be carried out via specified delivery routes including respiratory tract pathways.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?